SCHEMBL30656808

SCHEMBL30656808

COCCn1cnc2ccc(N)c(-c3ccc(C(F)(F)F)cc3)c2c1=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR3C1 P04150 2/20 0.39
BRD4 O60885 1/20 0.38
BRAF P15056 1/20 0.38
NSD2 O96028 1/20 0.37
NSD3 Q9BZ95 1/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
QPCT Q16769 2/20 0.36
KDM4E B2RXH2 2/20 0.35
ALDH1A1 P00352 2/20 0.35
HPGD P15428 2/20 0.35
HSD17B10 Q99714 2/20 0.35
NPC1 O15118 1/20 0.35
GLA P06280 1/20 0.35
GAA P10253 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
LCK P06239 1/20 0.35
KIT P10721 1/20 0.35
SRC P12931 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24166466 1.00 NR3C1 (0.39) NR3C1BRD4BRAFNSD2NSD3
SCHEMBL24165960 0.88 BRAF (0.41) BRAFMEN1KMT2AKDM4EALDH1A1
SCHEMBL30656795 0.88 BRAF (0.41) BRAFMEN1KMT2AKDM4EALDH1A1
SCHEMBL30656856 0.87 KMT2A (0.40) BRAFMEN1KMT2AKDM4EALDH1A1
SCHEMBL24166155 0.87 KMT2A (0.40) BRAFMEN1KMT2AKDM4EALDH1A1
SCHEMBL24166480 0.86 ALOX15 (0.46) NSD3MEN1KMT2AALDH1A1HSD17B10
SCHEMBL30656834 0.86 ALOX15 (0.46) NSD3MEN1KMT2AALDH1A1HSD17B10
SCHEMBL24166503 0.86 ALDH1A1 (0.43) BRAFMEN1KMT2AKDM4EALDH1A1
SCHEMBL30656811 0.86 ALDH1A1 (0.43) BRAFMEN1KMT2AKDM4EALDH1A1
SCHEMBL24166156 0.81 PIK3CA (0.43) BRAFMEN1KMT2AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12528777-B2 Quinazolinones derivatives for treatment of non-alcoholic fatty liver disease, preparation and use thereof COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2026-01-20 US disclosed
US-20230357165-A1 QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2023-11-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357165-A1 QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF ATG7, GOT1, LIPC NR3C1 1821/4885BRD4 1324/4885BRAF 4469/4885
US-12528777-B2 Quinazolinones derivatives for treatment of non-alcoholic fatty liver disease, preparation and use thereof ATG7, GOT1, ULK1 NR3C1 1383/4885BRD4 840/4885BRAF 4381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.